BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35893746)

  • 1. Discovery of Novel Dual Adenosine A
    Jung J; Lee Y; Moon AN; Ann J; Jeong JJ; Do N; Lee J
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 35893746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.
    Squarcialupi L; Falsini M; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Dal Ben D; Lambertucci C; Volpini R; Colotta V
    Bioorg Med Chem; 2016 Jun; 24(12):2794-808. PubMed ID: 27161878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility.
    Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Monopoli A; Ongini E; Varani K; Borea PA
    J Med Chem; 2002 Jan; 45(1):115-26. PubMed ID: 11754583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives with High Affinity for Both the Adenosine A
    Varano F; Catarzi D; Vigiani E; Dal Ben D; Buccioni M; Marucci G; Di Cesare Mannelli L; Lucarini E; Ghelardini C; Volpini R; Colotta V
    Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A
    Squarcialupi L; Betti M; Catarzi D; Varano F; Falsini M; Ravani A; Pasquini S; Vincenzi F; Salmaso V; Sturlese M; Varani K; Moro S; Colotta V
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):248-263. PubMed ID: 28114825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
    J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Aminopyrimidines as dual adenosine A1/A2A antagonists.
    Robinson SJ; Petzer JP; Terre'Blanche G; Petzer A; van der Walt MM; Bergh JJ; Lourens AC
    Eur J Med Chem; 2015 Nov; 104():177-88. PubMed ID: 26462195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A
    Varano F; Catarzi D; Falsini M; Vincenzi F; Pasquini S; Varani K; Colotta V
    Bioorg Med Chem; 2018 Jul; 26(12):3688-3695. PubMed ID: 29880250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
    Zheng J; Yang Z; Li X; Li L; Ma H; Wang M; Zhang H; Zhen X; Zhang X
    ACS Chem Neurosci; 2014 Aug; 5(8):674-82. PubMed ID: 24922583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-acting antitumor agents targeting the A
    Zhang J; Luo Z; Duan W; Yang K; Ling L; Yan W; Liu R; Wüthrich K; Jiang H; Xie C; Cheng J
    Eur J Med Chem; 2022 Jun; 236():114326. PubMed ID: 35390714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A₁ and A(2A) adenosine receptors. Molecular modeling and pharmacological studies.
    Squarcialupi L; Colotta V; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Borea PA; Porta N; Ciancetta A; Moro S
    Eur J Med Chem; 2014 Sep; 84():614-27. PubMed ID: 25063944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel and Selective Adenosine A
    Tian S; Wang X; Li L; Zhang X; Li Y; Zhu F; Hou T; Zhen X
    J Chem Inf Model; 2017 Jun; 57(6):1474-1487. PubMed ID: 28463561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
    Shiozaki S; Ichikawa S; Nakamura J; Kitamura S; Yamada K; Kuwana Y
    Psychopharmacology (Berl); 1999 Nov; 147(1):90-5. PubMed ID: 10591873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
    Baraldi PG; Cacciari B; Spalluto G; Pineda de las Infantas y Villatoro MJ; Zocchi C; Dionisotti S; Ongini E
    J Med Chem; 1996 Mar; 39(5):1164-71. PubMed ID: 8676354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C2-substituted quinazolinone derivatives exhibit A
    Pieterse L; van der Walt MM; Terre'Blanche G
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127274. PubMed ID: 32631506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.
    Yang M; Soohoo D; Soelaiman S; Kalla R; Zablocki J; Chu N; Leung K; Yao L; Diamond I; Belardinelli L; Shryock JC
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Apr; 375(2):133-44. PubMed ID: 17310264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: potent and selective adenosine A1 receptor antagonists.
    Poulsen SA; Quinn RJ
    J Med Chem; 1996 Oct; 39(21):4156-61. PubMed ID: 8863792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.
    Zhang X; Tellew JE; Luo Z; Moorjani M; Lin E; Lanier MC; Chen Y; Williams JP; Saunders J; Lechner SM; Markison S; Joswig T; Petroski R; Piercey J; Kargo W; Malany S; Santos M; Gross RS; Wen J; Jalali K; O'Brien Z; Stotz CE; Crespo MI; Díaz JL; Slee DH
    J Med Chem; 2008 Nov; 51(22):7099-110. PubMed ID: 18947224
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.